Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.53 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 2/20 | 0.52 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | IL1B | P01584 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | MAP1LC3B | Q9GZQ8 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16186470 | 0.92 | CRBN (0.44) | CRBNIKZF1CSNK1A1BRD4IKZF3 | |
| SCHEMBL4997427 | 0.88 | CRBN (0.56) | CRBNIKZF1CSNK1A1BRD4IKZF3 | |
| SCHEMBL1424366 | 0.86 | CRBN (0.52) | CRBNIKZF1CSNK1A1BRD4IKZF3 | |
| SCHEMBL1965099 | 0.86 | CRBN (0.63) | CRBNIKZF1CSNK1A1BRD4IKZF3 | |
| SCHEMBL1424399 | 0.85 | DDB1 (0.59) | CRBNIKZF1IKZF3DDB1TNF | |
| SCHEMBL1424450 | 0.84 | CRBN (0.55) | CRBNIKZF1CSNK1A1BRD4IKZF3 | |
| SCHEMBL1424862 | 0.84 | CRBN (0.59) | CRBNIKZF1CSNK1A1BRD4IKZF3 | |
| SCHEMBL4564524 | 0.84 | CRBN (0.60) | CRBNIKZF1CSNK1A1BRD4IKZF3 | |
| SCHEMBL1424690 | 0.84 | CRBN (0.61) | CRBNIKZF1CSNK1A1BRD4IKZF3 | |
| SCHEMBL1424745 | 0.84 | MAP1LC3B (0.54) | CRBNIKZF1CSNK1A1BRD4IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200113896-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARM LLC (US) | 2020-04-16 | — | — | US | disclosed |
| WO-2014172429-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND AN IMID COMPOUND FOR TREATING CANCER | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| US-20140314752-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140113935-A1 | N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2014-04-24 | — | — | US | disclosed |
| US-8648096-B2 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2014-02-11 | — | — | US | disclosed |
| US-8648096-B2 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2076260-B1 | N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2076260-B1 | N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20080214615-A1 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2008-09-04 | — | — | US | disclosed |
| WO-2008033567-A1 | N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214615-A1 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | INMT, HNMT, TPMT | CRBN 3001/4885IKZF1 1681/4885CSNK1A1 136/4885 |
| US-20200113896-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | MTOR, ULK1, RICTOR | CRBN 869/4885IKZF1 238/4885CSNK1A1 728/4885 |
| US-20140314752-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | MTOR, ULK1, RICTOR | CRBN 869/4885IKZF1 238/4885CSNK1A1 728/4885 |
| US-20140113935-A1 | N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | INMT, HNMT, TPMT | CRBN 3001/4885IKZF1 1681/4885CSNK1A1 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.